Liver Label Retaining Cancer Cells Are Relatively Resistant to the Reported Anti-Cancer Stem Cell Drug Metformin

Background & Aims: Recently, we reported that liver Label Retaining Cancer Cells (LRCC) can initiate tumors with only 10 cells and are relatively resistant to the targeted drug Sorafenib, a standard of practice in advanced hepatocellular carcinoma (HCC). LRCC are the only cancer stem cells (CSC)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cancer
Main Authors: Xin, Hong-Wu, Ambe, Chenwi M., Miller, Tyler C., Chen, Jin-Qiu, Wiegand, Gordon W., Anderson, Andrew J., Ray, Satyajit, Mullinax, John E., Hari, Danielle M., Koizumi, Tomotake, Godbout, Jessica D., Goldsmith, Paul K., Stojadinovic, Alexander, Rudloff, Udo, Thorgeirsson, Snorri S., Avital, Itzhak
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4911882/
https://ncbi.nlm.nih.gov/pubmed/27326258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.10047
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados